Abbott LaboratoriesNYSE: ABT
Health Care · Health Care Equipment
$89.66
-1.25%
Vol: 14.3M
Research Digest
Friday, May 1, 2026
Abbott trims full-year guidance citing Exact Sciences acquisition dilution despite Q1 beat, sending shares to 52-week lows
Abbott reported Q1 2026 adjusted EPS of $1.15 and revenue growth of 7.8%, both beating expectations, but the company lowered its full-year EPS guidance to $5.38-$5.58 due to $0.20 dilution from the March-closed $21 billion Exact Sciences acquisition. Shares have declined 26% year-to-date on concerns over Covid testing demand weakness and integration challenges. Abbott received FDA approval for its Ultreon 3.0 AI imaging platform. Analysts remain constructive with a median price target of $130.9, implying 44% upside.
Previous Market Intelligence
13 daysApr 30Abbott Q1 earnings beat, trimmed FY guidance to $5.38-$5.58 on $21B Exact Sciences acquisition dilutionMixed▶
Abbott reported Q1 2026 adjusted EPS of $1.15, beating expectations, with revenue climbing 7.8% to top forecasts. However, full-year EPS guidance was trimmed to $5.38-$5.58, citing $0.20 dilution from the March-closed $21 billion Exact Sciences acquisition, driving stock to new 52-week lows. Abbott secured FDA clearance and CE mark approval for Ultreon 3.0, an AI-powered coronary imaging platform, and CardioMEMS remote heart failure monitor. Management highlighted clinical data from pulsed field ablation and conduction system pacing portfolios. The stock faces headwinds from acquisition integration challenges despite strong operational execution and innovation. Street median price target is $120.50.
Apr 29Abbott Q1 adjusted EPS $1.15 beats, but FY26 EPS guidance cut to $5.38-$5.58 on $21B Exact Sciences dilutionMixed▶
Abbott Laboratories posted Q1 2026 adjusted EPS of $1.15 (vs. expectations) with revenue up 7.8% YoY, beating forecasts. However, full-year EPS guidance trimmed to $5.38-$5.58 range, reflecting $0.20 in dilution from completed $21B Exact Sciences acquisition (closed March 2026). Stock near 52-week lows down ~24% YTD. On positive side, company received FDA clearance and CE Mark for Ultreon 3.0 AI-powered coronary imaging platform on 4/28, and presented strong clinical data on pulsed field ablation and conduction system pacing at Heart Rhythm Society 2026. Board approved 2026 stock program and added Kevin Conroy to board. Analyst consensus: Strong Buy with median price target $120.5.
Apr 16Abbott faces $70 million jury award in infant formula litigation and reports Q1 earnings April 16 amid Exact Sciences $21B acquisition integrationMixed▶
Abbott Laboratories was ordered by a Chicago jury to pay $70 million in damages to families who claimed the company concealed that its premature-infant formula could cause necrotizing enterocolitis. The company faces over 1,700 additional lawsuits with potentially billions in exposure. Meanwhile, Abbott agreed to acquire Exact Sciences for $21 billion to expand its diagnostics portfolio in colorectal cancer screening. The company is scheduled to report Q1 2026 earnings on April 16, with analysts expecting $1.15 EPS and $10.99 billion in revenue. Goldman Sachs lowered its price target from $140 to $121 (Buy rating), while Barclays maintained Overweight and raised its target from $142 to $144.
Apr 14Goldman Sachs lowers Abbott PT to $121 on litigation risks; maintains BuyMixed▶
Goldman Sachs lowered PT to $121 on $70M infant formula verdict litigation. Citigroup and Barclays remain bullish. Extended Dividend Aristocrat status with 6.8% increase.
Apr 13Q1 2026 earnings April 16; $53M infant formula settlement; Abbott price targets raisedMixed▶
Abbott Laboratories to report Q1 2026 results on April 16 before market open. Chicago jury mandated $53M in compensatory damages over infant formula NEC claims (Apr 10). Goldman Sachs initiated Buy (Apr 8); Barclays raised price target to $144 from $142. FreeStyle Libre diabetes data shows 0.6% HbA1c reduction advantage. Stock at $100.25.
Apr 10Abbott invests in Whoop's funding round; Q1 earnings April 16; Goldman Sachs lowers target.Negative▶
Abbott trading at $102.30, near 52-week lows. Goldman Sachs cut price target from $140 to $121. Abbott invested in Whoop's $575 million Series E funding round expanding digital health footprint. Q1 2026 results April 16 before market open. Average analyst target is $132.05 with 28.43% upside potential.
Apr 9Abbott Laboratories Digital Health Push: Whoop $575M Investment; Leadership ShakeupPositive▶
Abbott invested in Whoop's $575M funding round to boost digital health and wearables offerings. Company chairman/CEO made insider purchase of 18,800 shares, though TAVR division leader Chris Waddell is leaving. Stock at 103.56, up 1.70% on April 8, with strong Nutrition and Diabetes Care growth.
Apr 8Abbott Q1 2026 earnings April 16; Whoop investment $575M; diagnostics slowdown concerns.Neutral▶
Abbott will announce Q1 2026 results April 16. Investing $575 million in Whoop's funding round. Board authorized 6.8% dividend increase to $0.63 (ex-date April 15). Stock under pressure after diagnostics slowdown amid post-pandemic demand shift. BTIG lowered target to $131 from $140. Average target $137.47.
Apr 7Abbott completes $11B Exact Sciences acquisition, projects 2026 organic sales +6.5-7.5% and EPS $5.55-5.80Positive▶
Abbott completed $11B Exact Sciences acquisition on March 23, establishing leadership in cancer screening and precision oncology diagnostics. Company reported Q4 2025 adjusted EPS $1.50 (+12%) with full-year adjusted EPS $5.15 (+10%). Abbott projects 2026 organic sales growth 6.5-7.5% and adjusted diluted EPS $5.55-5.80. Volt Pulsic Field Ablation System showed 84.2% PAF and ~68% persistent AF freedom at 12 months. CE Mark received January 2026 for TactiFlex Duo catheter. Board approved 6.8% dividend increase to $0.63/share (54th consecutive year). Q1 2026 earnings April 16.
Apr 6Abbott completes Exact Sciences acquisition; integrates oncology into Flatiron OncoEMR.Positive▶
Abbott completed Exact Sciences acquisition March 23, adding Cologuard. Integrated Abbott Precision Oncology into Flatiron OncoEMR (March 30) reaching 1,600+ cancer centers and 4,700 providers. CEO bought 18,800 shares. BTIG lowered PT to $131 from $140. Average target $137.71 (34% upside).
Apr 3Abbott completes Exact Sciences acquisition; Q1 earnings April 16 amid strong digital health positioning.Positive▶
Abbott completed acquisition of Exact Sciences, expanding cancer diagnostics portfolio. Q4 2025: adjusted diluted EPS $1.50 (+12%); 2026 guidance: 6.5-7.5% organic growth, adjusted EPS $5.55-$5.80. Dividend raised 6.8% to $0.63 (54th consecutive year). CardioMEMS reader received FDA approval. Volt Pulsed Field Ablation System showed 84.2% freedom from PAF recurrence at 12 months. Q1 earnings April 16. Analysts target $137.71.
Apr 1Abbott closes Exact Sciences acquisition (March 23); projects $5.55-$5.80 2026 EPS with 6.5-7.5% organic growth.Positive▶
Abbott completed the $8.3 billion Exact Sciences acquisition on March 23, 2026, expected to add ~$3 billion incremental 2026 sales but dilute EPS by ~$0.20. The company projects 2026 organic sales growth of 6.5%-7.5% and adjusted EPS of $5.55-$5.80. Abbott reported strong AFib ablation device results and increased dividend 6.8% to $0.63. Analyst consensus shows 76% Buy ratings with average price target of $128.52.
Mar 31Abbott completed Exact Sciences acquisition March 23; integrated precision oncology into Flatiron 1,600+ cancer centers.Neutral▶
Abbott completed Exact Sciences acquisition March 23 adding Cologuard. Integrated Precision Oncology into Flatiron OncoEMR across 1,600+ cancer centers. Volt ablation and CardioMEMS received FDA approval. Q1 earnings April 16. Stock at 52-week low $102.39.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
| EWEDWARDS | $84.28 | +0.93% | +2.9% | 24.8x | 0.94 | $48.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.